Showing results (51-60 of 81) with videos related to

Sort By:
Pageof 9
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 6, 2012
Randomized, phase III study of gemcitabine or erlotinib maintenance therapy versus observation, with predefined second-line treatment, after cisplatin-gemcitabine induction chemotherapy in advanced non-small-cell lung cancerMaurice Pérol, Christos Chouaid, David Pérol, et al.
Lung Cancer (Amsterdam, Netherlands)|March 22, 2025
Clinical characteristics and management of long survivors in extensive stage small cell lung cancerElisa Gobbini, Mamadou Hassimiou Diallo, David Pasquier, et al.
Cancer Immunology, Immunotherapy : CII|June 21, 2022
First-line single-agent pembrolizumab for PD-L1-positive (tumor proportion score ≥ 50%) advanced non-small cell lung cancer in the real world: impact in brain metastasis: a national French multicentric cohort (ESCKEYP GFPC study)Renaud Descourt, Laurent Greillier, Maurice Perol, et al.
JCO Precision Oncology|September 11, 2020
Efficacy of Vemurafenib in Patients With Non-Small-Cell Lung Cancer With <i>BRAF</i> V600 Mutation: An Open-Label, Single-Arm Cohort of the Histology-Independent VE-BASKET StudyVivek Subbiah, Radj Gervais, Gregory Riely, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 9, 2019
Health-Related Quality of Life Impact from Adding Bevacizumab to Cisplatin-Pemetrexed in Malignant Pleural Mesothelioma in the MAPS IFCT-GFPC-0701 Phase III TrialGuillaume Eberst, Amélie Anota, Arnaud Scherpereel, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 5, 2014
The impact of EGFR T790M mutations and BIM mRNA expression on outcome in patients with EGFR-mutant NSCLC treated with erlotinib or chemotherapy in the randomized phase III EURTAC trialCarlota Costa, Miguel Angel Molina, Ana Drozdowskyj, et al.
Clinical Lung Cancer|June 24, 2014
Oral vinorelbine plus cisplatin as first-line chemotherapy in nonsquamous non-small-cell lung cancer: final results of an International randomized phase II study (NAVotrial 01)Jaafar Bennouna, Libor Havel, Maciej Krzakowski, et al.
Clinical Lung Cancer|October 26, 2019
Phase II Study Evaluating the Mechanisms of Resistance on Tumor Tissue and Liquid Biopsy in Patients With EGFR-mutated Non-pretreated Advanced Lung Cancer Receiving Osimertinib Until and Beyond Radiologic Progression: The MELROSE TrialJaafar Bennouna, Nicolas Girard, Clarisse Audigier-Valette, et al.
Lancet (London, England)|January 1, 2016
Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trialGérard Zalcman, Julien Mazieres, Jacques Margery, et al.
The Lancet. Oncology|January 5, 2016
TG4010 immunotherapy and first-line chemotherapy for advanced non-small-cell lung cancer (TIME): results from the phase 2b part of a randomised, double-blind, placebo-controlled, phase 2b/3 trialElisabeth Quoix, Hervé Lena, Gyorgy Losonczy, et al.
Pageof 9